Page 1 of 48
NAPSRx CNPR EXAM AND STUDY GUIDE LATEST 2025
TEST BANK| COMPLETE REAL EXAM QUESTIONS AND
CORRECT DETAILED ANSWERS (VERIFIED ANSWERS)
ALREADY GRADED A+| REVISED 18TH EDITION| 2025
NEWEST!!
STAT order .....ANSWER..... a drug needed immediately and
given only once
Overdosage section of labeling .....ANSWER..... signs, symptoms
and treatment of acute overdoses
Types of drug-drug interactions .....ANSWER..... duplication,
opposition (antagonism) and alteration
Tolerance vs Resistance .....ANSWER..... tolerance is the
diminished response to a drug; resistance is the cells ability to
resist the effects of the drug on them.
,Page 2 of 48
Abbreviated New Drug Application (ANDA) .....ANSWER..... the
process by which applicants must scientifically demonstrate to the
FDA that their generic product is bioequivalent to or performs in
the same way as the innovator drug, no duplicate testing
Hatch-Waxman Act of 1984 .....ANSWER..... A.K.A. Drug Price
Competition and Patent Restoration Act; made it easier to bring
generic drugs to the market by requiring the FDA to only look at
bioavailability studies in order to approve an ANDA; gave
protection to the research based manufacturers by providing a
30-month automatic cooling off period once an ANDA is
challenged for patent infringement.
Four basic transport mechanisms .....ANSWER..... passive diffusion,
facilitated diffusion, active transport, and pinocytosis
Potency vs Efficacy .....ANSWER..... potency: amount of drug
necessary to produce desired effect; efficacy: magnitude of
,Page 3 of 48
maximal response that can be received from a drug; efficacy is
almost always more important than potency.
Four phases of clinical trials .....ANSWER..... phases I-IV
Key Parts Of A Clinical Paper .....ANSWER..... Abstract,
Introduction, methods, results, discussion/conclusions
Reliability vs Validity .....ANSWER..... reliability = consistency
and validity = accuracy
Sampling error vs Selection bias .....ANSWER..... sampling error is
unbiased and is randomly chosen from the population; selection
bias is when the sample was specifically chosen based on
particular characteristics.
Independent vs Dependent variable .....ANSWER..... An
independent variable is the one that influences the variation. A
dependent variable is the variable being tested and measured
in a scientific experiment.
, Page 4 of 48
Drug Utilization Review (DUR) programs .....ANSWER..... involve
retrospective monitoring of physicians' prescribing patterns; more
than 90% of HMOs require DURs; nowadays mostly monitors cost
savings.
Opportunity cost .....ANSWER..... based on the premise that all
resources are scarce, and therefore every time we choose to use
a resource it reduces the possibility of it being used in another
way.
DTC advertising in Europe .....ANSWER..... Disease-state or
unbranded ads (provides public information on a disease, not a
drug)
PhRMA code on meals .....ANSWER..... company reps can only
offer occasional meals as long as they are modest, and only
offered in an office/hospital setting in conjunction with an
educational presentation.
FAQ about the PhRMA code .....ANSWER..... p. 268-274
NAPSRx CNPR EXAM AND STUDY GUIDE LATEST 2025
TEST BANK| COMPLETE REAL EXAM QUESTIONS AND
CORRECT DETAILED ANSWERS (VERIFIED ANSWERS)
ALREADY GRADED A+| REVISED 18TH EDITION| 2025
NEWEST!!
STAT order .....ANSWER..... a drug needed immediately and
given only once
Overdosage section of labeling .....ANSWER..... signs, symptoms
and treatment of acute overdoses
Types of drug-drug interactions .....ANSWER..... duplication,
opposition (antagonism) and alteration
Tolerance vs Resistance .....ANSWER..... tolerance is the
diminished response to a drug; resistance is the cells ability to
resist the effects of the drug on them.
,Page 2 of 48
Abbreviated New Drug Application (ANDA) .....ANSWER..... the
process by which applicants must scientifically demonstrate to the
FDA that their generic product is bioequivalent to or performs in
the same way as the innovator drug, no duplicate testing
Hatch-Waxman Act of 1984 .....ANSWER..... A.K.A. Drug Price
Competition and Patent Restoration Act; made it easier to bring
generic drugs to the market by requiring the FDA to only look at
bioavailability studies in order to approve an ANDA; gave
protection to the research based manufacturers by providing a
30-month automatic cooling off period once an ANDA is
challenged for patent infringement.
Four basic transport mechanisms .....ANSWER..... passive diffusion,
facilitated diffusion, active transport, and pinocytosis
Potency vs Efficacy .....ANSWER..... potency: amount of drug
necessary to produce desired effect; efficacy: magnitude of
,Page 3 of 48
maximal response that can be received from a drug; efficacy is
almost always more important than potency.
Four phases of clinical trials .....ANSWER..... phases I-IV
Key Parts Of A Clinical Paper .....ANSWER..... Abstract,
Introduction, methods, results, discussion/conclusions
Reliability vs Validity .....ANSWER..... reliability = consistency
and validity = accuracy
Sampling error vs Selection bias .....ANSWER..... sampling error is
unbiased and is randomly chosen from the population; selection
bias is when the sample was specifically chosen based on
particular characteristics.
Independent vs Dependent variable .....ANSWER..... An
independent variable is the one that influences the variation. A
dependent variable is the variable being tested and measured
in a scientific experiment.
, Page 4 of 48
Drug Utilization Review (DUR) programs .....ANSWER..... involve
retrospective monitoring of physicians' prescribing patterns; more
than 90% of HMOs require DURs; nowadays mostly monitors cost
savings.
Opportunity cost .....ANSWER..... based on the premise that all
resources are scarce, and therefore every time we choose to use
a resource it reduces the possibility of it being used in another
way.
DTC advertising in Europe .....ANSWER..... Disease-state or
unbranded ads (provides public information on a disease, not a
drug)
PhRMA code on meals .....ANSWER..... company reps can only
offer occasional meals as long as they are modest, and only
offered in an office/hospital setting in conjunction with an
educational presentation.
FAQ about the PhRMA code .....ANSWER..... p. 268-274
